Tell us about your biggest client wins this year. Class certification was granted in both In re Loestrin 24 FE Antitrust Litigation and In re Niaspan Antitrust Litigation, which both allege that drug manufacturers unlawfully delayed and impaired generic competition. [The firm] also defeated defendants’ motions to dismiss in In re Zetia (Ezetimibe) Antitrust Litigation, another pay-for-delay case alleging that defendants Merck and Glenmark kept generic Zetia off the market, and in In re Generic Pharmaceuticals Pricing Antitrust Litigation, one of the largest [multidistrict litigation] cases in the county, involving allegations of widespread price-fixing among generic drug manufacturers.

What’s the best lesson you learned as a young lawyer? The facts matter—a lot.